Nicox’s NCX 470 NDA gains acceptance for review in China, advancing its glaucoma therapy toward the world’s second‑largest pharmaceutical market
Executive summary: Nicox received acceptance for review of its NDA for NCX 470 from China’s drug regulator. This advances the therapy toward potential launch in China, the world’s second‑largest pharmaceutical market, and could enhance Nicox’s revenue prospects.
Who is involved: Nicox, its partner Ocumension, and China’s National Medical Products Administration (NMPA).
Likely next: The NMPA will conduct a substantive review, with a decision expected according to its standard timeline.
Nicox announced that China’s drug regulator has accepted its New Drug Application (NDA) for NCX 470 for review. This marks the first regulatory step toward potential marketing approval of the ophthalmic compound in China. The acceptance follows an earlier submission announcement by Nicox’s partner Ocumension in August 2026.
What's next — scenarios
Base: standard approval within 12 months (50%)
Nicox could launch NCX 470 in China by late 2027, adding ophthalmic sales.
- No major safety concerns identified during review
- NMPA completes review on schedule
- Nicox responds promptly to any information requests
Upside: accelerated/priority review leading to approval in 6‑9 months (30%)
Earlier market entry would boost near‑term revenue and strengthen Nicox’s position in Chinese glaucoma therapy.
- NMPA grants priority review based on unmet medical need
- Positive interim data submitted
- No significant deficiencies found
Downside: request for additional data delaying approval beyond 18 months (20%)
Delay would postpone revenue and increase development costs for Nicox.
- NMPA identifies gaps in submitted data
- Nicox required to conduct supplementary study
- Regulatory feedback indicates need for larger safety database
What to watch
- NMPA decision on NCX 470 NDA expected by September 2027 (standard 12‑month review window).
- Nicox interim update on review status expected Q4 2026.
- Ocumension communication regarding any additional data requests from NMPA.
- Any press release from Nicox addressing post‑marketing commitments if approved.
Timeline
- — Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470 (GlobeNewswire)
- — Nicox Announces NCX 470 NDA in China Accepted for Review (GlobeNewswire)
- — Nicox annonce la soumission d’une NDA pour NCX 470 en Chine par son partenaire Ocumension (GlobeNewswire)
- — Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension (GlobeNewswire)
Analysis — what this means
Likely next events
- NMPA to complete standard review of NCX 470 NDA, with decision expected by September 2027 (based on typical 12‑month review cycle).
- Nicox may release an interim update on the review status within Q4 2026.
- Ocumension could provide additional clinical data if requested by NMPA during review.
Sectors affected
- Glaucoma treatment market in China
- Ophthalmic drug development sector
Regulatory implications
- Acceptance triggers substantive review by China’s NMPA
- If approved, NCX 470 would be classified as a Class 3 new drug requiring post‑marketing surveillance
- The NDA follows a review process independent of the US PDUFA timeline
Historical parallels
- Nicox’s August 10 2026 announcement of NCX 470 NDA submission to China by partner Ocumension
- Raziel Therapeutics and Fosun Pharma’s September 2 2026 disclosure of positive Phase 3 results for RZL‑012, clearing the path to a China NDA filing
Key entities
Sources
- Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470 — GlobeNewswire
- Nicox Announces NCX 470 NDA in China Accepted for Review — GlobeNewswire
- Nicox annonce la soumission d’une NDA pour NCX 470 en Chine par son partenaire Ocumension — GlobeNewswire
- Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension — GlobeNewswire
Related cases
- Nicox’s NCX 470 gains regulatory traction in China as its NDA is accepted for review
- China’s new Arctic maritime route signals a strategic move to reveal broader geopolitical ambitions
- US declares national emergency on power grid to block Chinese equipment imports, aiming to secure domestic electricity infrastructure
- China’s push to deploy humanoid robots aims to counter its aging workforce and boost its robotics industry
- Australia ramps up rare earth refining capacity to challenge China's dominance
- Ocumension files NDA in China for Nicox’s NCX 470 glaucoma therapy, marking a key regulatory milestone for the ophthalmic asset